Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;13(1):113-21.
doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians

Affiliations

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians

Kevin C Brown et al. Pharmacogenomics. 2012 Jan.

Abstract

Aim: Genetic polymorphisms have the potential to influence drug metabolism and vary among ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine pharmacokinetics exposure in Malawians.

Materials & methods: CYP450 2B6, 2D6, 3A4 and 3A5, ABCB1 and constitutive androstane receptor and pregnane X receptor, were analyzed for polymorphisms in 26 subjects.

Results: Allele frequencies (variant) were: CYP2B6 514G>T (0.31) CYP2D6*4 (0.02); CYP2D6*17 (0.35); CYP3A4*1B (0.77); CYP3A5*3 (0.25); ABCB1 2677G>T (0.0), ABCB1 3435C>T (0.21), NR1I3 13711152T>C (0.02), NR1I2 44477T>C (0.10), NR1I2 63396C>T (0.33), NR1I2 6-bp indel (del: 0.17). CYP2B6 516G>T (non-wild-type/wild-type) correlated with nevirapine pharmacokinetic parameters; geometric mean ratios (95% CI): 1.75 (1.27-2.40) for area under the concentration time curve (AUC)(0-12 h), 1.58 (1.03-2.42) for C(0), and 0.53 (0.31-0.91) for clearance. In a multivariable model, nevirapine AUC increased by 1.5% per year of age (p < 0.0001), CYP2B6 516 T allele increased AUC by 92% (p < 0.0001), and CYP3A5*3 decreased AUC by 31% (p = 0.0027).

Conclusion: Allele frequencies were similar to other sub-Saharan African populations. The T allele for CYP2B6 516 was significantly associated with nevirapine exposure.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Weight-adjusted clearance versus CYP2D6*17 genotype (*17 = T allele) in the pediatric group and adult group
(A) Pediatric group, (B) Adult group. CL: Clearance.

References

    1. Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–549. - PubMed
    1. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15(1):1–5. First paper to describe CYP2B6 polymorphisms and effects on nevirapine therapy. - PubMed
    1. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229–243. - PubMed
    1. Haas DW, Wu H, Li H, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult aids clinical trials group study. J Acquir Immune Defic Syndr. 2003;34(3):295–298. - PubMed
    1. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an adult aids clinical trials group study. AIDS. 2004;18(18):2391–2400. - PubMed

Websites

    1. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services; Jan 10, 2011. [Accessed 15 May 2011]. pp. 1–166. www.Aidsinfo.Nih.Gov/contentfiles/adultandadolescentgl.Pdf.
    1. FAO Malawi nutrition profile. Nutrition and Consumer Protection Division. Food and Agriculture Organization of the United Nations; 2008. [Accessed 26 May 2010]. www.fao.org/ag/agn/nutrition/mwi_en.stm.
    1. NCBI dbSNP. www.ncbi.nlm.nih.gov/snp.

Publication types

MeSH terms